Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director Cyrus Taraporevala acquired 1,506.024 phantom stock units as deferred compensation, increasing his total beneficial ownership to 25,349.741 units.

Summary

• Cyrus Taraporevala, a Director at Pfizer Inc. (PFE), acquired 1,506.024 phantom stock units.
• The transaction occurred on December 31, 2025, and was made pursuant to a Rule 10b5-1(c) plan.
• Each phantom stock unit represents one phantom share of common stock, priced at $24.9 per unit.
• Following this acquisition, Mr. Taraporevala beneficially owns a total of 25,349.741 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents, and will be settled in cash or common stock at the director's election upon retirement from the Board of Directors.

Sentiment

Score: 5

Explanation: The filing reports a routine acquisition of phantom stock units as deferred compensation for a director, which is a neutral event for company operations and stock performance.

Positives

• Director's beneficial ownership of phantom stock units increased by 1,506.024 units, enhancing alignment with shareholder interests.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Acquisition of phantom stock units by a director as deferred compensation, which is a standard related party transaction for executive remuneration.

Stakeholder Impact

• Increased alignment of director's interests with shareholders through beneficial ownership of phantom stock units, potentially fostering long-term decision-making.

Next Steps

• Settlement of phantom stock units in cash or common stock upon the director's retirement from the Board of Directors.

Key Dates

Keywords

Pfizer, PFE, Cyrus Taraporevala, Phantom Stock Units, Director Compensation, SEC Form 4, Insider Transaction, Deferred Compensation, Rule 10b5-1